Background: The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal pol- yposis (CRSwNP). Methods: For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. Results: 695 patients with severe asthma enrolled in 66 SANI centers were analyzed. The prevalence of chronic rhinosinusitis with nasal polyposis was 40.6%. Atopic dermatitis and bronchiectasis was significantly more frequent in patients with CRSwNP than in subjects without nasal polyposis; similarly, FeNO values are signifi- cantly higher in subject with CRSwNP than in patients without nasal polyposis. Finally, patients with CRSwNP had a significantly higher number of asthma exacerbations per year, more days on oral corticosteroids and were more likely to be OCS long term users. Conclusion: OCS sparing is needed in patients with severe asthma, mainly in subjects with CRSwNP, adopting adequate strategies such as a better adherence to the treatment with inhaled therapy according to the GINA recommendations, the use of biologic agents and a multidisciplinary approach of the patient.
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry / Canonica, G. W.; Malvezzi, L. c.; Blasi, F. d.; Paggiaro, P. e.; Mantero, M. d.; Senna, G. f.; Heffler, E. a.; B, ; Bonavia, M.; Caiaffa, P.; Calabrese, C.; Camiciottoli, G.; Caruso, C.; Centanni, S.; Conte, M. E.; Corsico, A. G.; Cosmi, L.; Costantino, M. T.; Crimi, N.; D'Alò, S.; D'Amato, M.; Del Giacco, S.; Favero, E.; Farsi, A.; Foschino, B. P. M.; Guarnieri, G.; Guida, G.; Latorre, M.; Lombardi, C.; Macchia, L.; Menzella, F.; Milanese, M.; Montuschi, P.; Nucera, E.; Parente, R.; Passalacqua, G.; Patella, V.; Pelaia, G.; Pini, L.; Ricciardolo, F. L. M.; Ricciardi, L.; Richeldi, L.; Ridolo, E.; Rolla, G.; Santus, P.; Scichilone, N.; Solidoro, P.; Spadaro, G.; Spanevello, A.; Vianello, A; Yacoub, M; Zappa, Mc. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - 166:(2020).
Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry
Yacoub MPenultimo
;
2020-01-01
Abstract
Background: The clinical and laboratory features of patients enrolled in the Severe Asthma Network in Italy (SANI) registry, a web-based observatory collecting demographic, clinical, functional and inflammatory data of patients with severe asthma were evaluated, with a special emphasis to chronic rhinosinusitis with nasal pol- yposis (CRSwNP). Methods: For each eligible patients the following information has been collected: demographic data, clinical features, asthma control in the previous month according to the GINA (Global INitiative for Asthma) Guidelines and standardized questionnaires, concomitant regular and on demand treatments and inflammatory markers. Results: 695 patients with severe asthma enrolled in 66 SANI centers were analyzed. The prevalence of chronic rhinosinusitis with nasal polyposis was 40.6%. Atopic dermatitis and bronchiectasis was significantly more frequent in patients with CRSwNP than in subjects without nasal polyposis; similarly, FeNO values are signifi- cantly higher in subject with CRSwNP than in patients without nasal polyposis. Finally, patients with CRSwNP had a significantly higher number of asthma exacerbations per year, more days on oral corticosteroids and were more likely to be OCS long term users. Conclusion: OCS sparing is needed in patients with severe asthma, mainly in subjects with CRSwNP, adopting adequate strategies such as a better adherence to the treatment with inhaled therapy according to the GINA recommendations, the use of biologic agents and a multidisciplinary approach of the patient.File | Dimensione | Formato | |
---|---|---|---|
1-s2.0-S0954611120300871-main.pdf
solo gestori archivio
Tipologia:
PDF editoriale (versione pubblicata dall'editore)
Licenza:
Copyright dell'editore
Dimensione
477.64 kB
Formato
Adobe PDF
|
477.64 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.